Sarepta
Therapeutics Inc. (Nasdaq: SRPT) will submit a rolling New Drug Application
for its Duchenne muscular dystrophy treatment eteplirsen. Shares of the biopharmaceutical leaped $9.95 to $26.33.
Sarepta to submit rolling NDA
May 20, 2015 at 13:07 PM EDT
